213 related articles for article (PubMed ID: 27679514)
1. A Novel Hybrid Compound LLP2A-Ale Both Prevented and Rescued the Osteoporotic Phenotype in a Mouse Model of Glucocorticoid-Induced Osteoporosis.
Mohan G; Lay EY; Berka H; Ringwood L; Kot A; Chen H; Yao W; Lane NE
Calcif Tissue Int; 2017 Jan; 100(1):67-79. PubMed ID: 27679514
[TBL] [Abstract][Full Text] [Related]
2. Improved Mobilization of Exogenous Mesenchymal Stem Cells to Bone for Fracture Healing and Sex Difference.
Yao W; Lay YE; Kot A; Liu R; Zhang H; Chen H; Lam K; Lane NE
Stem Cells; 2016 Oct; 34(10):2587-2600. PubMed ID: 27334693
[TBL] [Abstract][Full Text] [Related]
3. A new anabolic compound, LLP2A-Ale, reserves periodontal bone loss in mice through augmentation of bone formation.
Jiang M; Liu L; Liu R; Lam KS; Lane NE; Yao W
BMC Pharmacol Toxicol; 2020 Nov; 21(1):76. PubMed ID: 33187558
[TBL] [Abstract][Full Text] [Related]
4. A novel hybrid compound LLP2A-alendronate accelerates open fracture healing in a rabbit model.
Wang Z; Zhao Y; Zhang D; Qi B; Xiao W; Hu X; Yu A
Drug Des Devel Ther; 2019; 13():1077-1086. PubMed ID: 31040645
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of glucocorticoid induced osteonecrosis in the mouse is not affected by treatments that maintain bone vascularity.
Lane NE; Mohan G; Yao W; Shidara K; Lay YE; Junjing J; Dubrovsky A; Kimmel DB
Bone Rep; 2018 Dec; 9():181-187. PubMed ID: 30510976
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of mesenchymal stem cells to the bone.
Yao W; Lane NE
Bone; 2015 Jan; 70():62-5. PubMed ID: 25173607
[TBL] [Abstract][Full Text] [Related]
7. Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.
Yao W; Dai W; Jiang L; Lay EY; Zhong Z; Ritchie RO; Li X; Ke H; Lane NE
Osteoporos Int; 2016 Jan; 27(1):283-294. PubMed ID: 26384674
[TBL] [Abstract][Full Text] [Related]
8. A novel flavonoid C-glucoside from Ulmus wallichiana preserves bone mineral density, microarchitecture and biomechanical properties in the presence of glucocorticoid by promoting osteoblast survival: a comparative study with human parathyroid hormone.
Khan MP; Mishra JS; Sharan K; Yadav M; Singh AK; Srivastava A; Kumar S; Bhaduaria S; Maurya R; Sanyal S; Chattopadhyay N
Phytomedicine; 2013 Nov; 20(14):1256-66. PubMed ID: 23928508
[TBL] [Abstract][Full Text] [Related]
9. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass.
Guan M; Yao W; Liu R; Lam KS; Nolta J; Jia J; Panganiban B; Meng L; Zhou P; Shahnazari M; Ritchie RO; Lane NE
Nat Med; 2012 Feb; 18(3):456-62. PubMed ID: 22306732
[TBL] [Abstract][Full Text] [Related]
10. Reversing bone loss by directing mesenchymal stem cells to bone.
Yao W; Guan M; Jia J; Dai W; Lay YA; Amugongo S; Liu R; Olivos D; Saunders M; Lam KS; Nolta J; Olvera D; Ritchie RO; Lane NE
Stem Cells; 2013 Sep; 31(9):2003-14. PubMed ID: 23818248
[TBL] [Abstract][Full Text] [Related]
11. The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment.
Oxlund H; Ortoft G; Thomsen JS; Danielsen CC; Ejersted C; Andreassen TT
Bone; 2006 Aug; 39(2):244-52. PubMed ID: 16503210
[TBL] [Abstract][Full Text] [Related]
12. Short-term glucocorticoid excess blunts abaloparatide-induced increase in femoral bone mass and strength in mice.
Brent MB; Thomsen JS; Brüel A
Sci Rep; 2021 Jun; 11(1):12258. PubMed ID: 34112892
[TBL] [Abstract][Full Text] [Related]
13. Yeast-incorporated gallium attenuates glucocorticoid-induced bone loss in rats by inhibition of bone resorption.
Ren Z; Yang L; Xue F; Meng Q; Wang K; Wu X; Ji C; Jiang T; Liu D; Zhou L; Zhang J; Fu Q
Biol Trace Elem Res; 2013 Jun; 152(3):396-402. PubMed ID: 23532566
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization.
Yao W; Cheng Z; Pham A; Busse C; Zimmermann EA; Ritchie RO; Lane NE
Arthritis Rheum; 2008 Nov; 58(11):3485-97. PubMed ID: 18975341
[TBL] [Abstract][Full Text] [Related]
15. Prevention of glucocorticoid induced bone changes with beta-ecdysone.
Dai W; Jiang L; Lay YA; Chen H; Jin G; Zhang H; Kot A; Ritchie RO; Lane NE; Yao W
Bone; 2015 May; 74():48-57. PubMed ID: 25585248
[TBL] [Abstract][Full Text] [Related]
16. Effects of the combined Herba Epimedii and Fructus Ligustri Lucidi on bone turnover and TGF-β1/Smads pathway in GIOP rats.
Yang Y; Nian H; Tang X; Wang X; Liu R
J Ethnopharmacol; 2017 Apr; 201():91-99. PubMed ID: 28254481
[TBL] [Abstract][Full Text] [Related]
17. Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats.
Cheng Z; Yao W; Zimmermann EA; Busse C; Ritchie RO; Lane NE
J Bone Miner Res; 2009 Feb; 24(2):209-20. PubMed ID: 18847326
[TBL] [Abstract][Full Text] [Related]
18. Influence of glucocorticoid on bone in 3-, 6-, and 12-month-old rats as determined by bone mass and histomorphometry.
Ogoshi T; Hagino H; Fukata S; Tanishima S; Okano T; Teshima R
Mod Rheumatol; 2008; 18(6):552-61. PubMed ID: 18648735
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid-induced osteoporosis in growing mice is not prevented by simultaneous intermittent PTH treatment.
Postnov A; De Schutter T; Sijbers J; Karperien M; De Clerck N
Calcif Tissue Int; 2009 Dec; 85(6):530-7. PubMed ID: 19844646
[TBL] [Abstract][Full Text] [Related]
20. [Glucocorticoid and bone metabolism and disease].
Tanaka Y
Clin Calcium; 2013 Feb; 23(2):229-35. PubMed ID: 23354090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
